1. Home
  2. AOMR vs NGEN Comparison

AOMR vs NGEN Comparison

Compare AOMR & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AOMR

Angel Oak Mortgage REIT Inc.

HOLD

Current Price

$8.27

Market Cap

218.7M

Sector

Real Estate

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$1.87

Market Cap

175.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AOMR
NGEN
Founded
2018
2017
Country
United States
Canada
Employees
N/A
9
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
218.7M
175.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
AOMR
NGEN
Price
$8.27
$1.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$11.08
$18.00
AVG Volume (30 Days)
119.3K
1.2M
Earning Date
05-05-2026
04-02-2026
Dividend Yield
14.18%
N/A
EPS Growth
53.85
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.96
$1.87
52 Week High
$10.14
$5.93

Technical Indicators

Market Signals
Indicator
AOMR
NGEN
Relative Strength Index (RSI) 46.04 25.23
Support Level $8.10 N/A
Resistance Level $8.91 $4.52
Average True Range (ATR) 0.18 0.15
MACD -0.01 -0.08
Stochastic Oscillator 57.52 1.05

Price Performance

Historical Comparison
AOMR
NGEN

About AOMR Angel Oak Mortgage REIT Inc.

Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: